NCT03750786已完成3 期
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 490
- 试验地点
- 94
- 主要终点
- Overall Response Rate
研究概览
简要总结
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab according to modified FOLFOX-6 until PD according to RECIST 1.1 criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Colorectal adenocarcinoma verified by biopsy.
- •Availability of biopsy material, from the primary tumor or metastasis, allowing for analysis of tumor gene expression.
- •Non-resectable metastatic CRC planned for first line therapy with 5-FU, Leucovorin, oxaliplatin, and bevacizumab.
- •Evaluable disease with at least one measurable lesion of metastatic disease (≥10 mm in longest diameter on axial image on CT-scan or alternatively MRI with <5 mm reconstruction interval) or lymph node (≥ 15 mm in shortest axis when assessed by CT) obtained within 28 days of randomization.
- •Life expectancy of more than 4 months.
- •ECOG performance status 0 or
- •Hemoglobin (Hb) > 80 g/L, Absolute neutrophil count (ANC) > 1.5x10E9/L. Thrombocytes > 100x10E9/L.
- •Creatinine clearance > 50 mL/min, Total bilirubin < 1.5 x ULN, AST and ALT < 3 x ULN (and < 5 x ULN in case of liver metastases).
- •Male or female ≥18 years of age.
- •Female patients of childbearing potential must have a negative urine pregnancy test and use adequate contraceptive measures . Male patients must use adequate contraceptive measures .
- •Voluntarily signed informed consent before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
排除标准
- •Malignant tumors other than colorectal adenocarcinomas (current or within the previous five years), with the exception for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix.
- •Less than 6 months between randomization and completion of the last anti-cancer treatment (chemotherapy/radiotherapy/immunotherapy, etc.). (NB: Rectal cancer treatment shorter than 8 weeks of chemo/radiation therapy is allowed.)
- •Confirmation of progressive disease within 6 months after completion of prior adjuvant anti-cancer treatment.
- •Indication for any metastatic Colo-rectal Cancer (mCRC) surgery or anti-cancer treatment other than study treatment.
- •Prior treatment with arfolitixorin.
- •Indication for treatment with a 5-FU analogue, or 5-FU for a condition other than mCRC.
- •Known Dihydropyrimidine Dehydrogenase Deficiency (DPD) deficiency.
- •Known or suspected central nervous system (CNS) metastases.
- •Unresolved bowel obstruction, uncontrolled Crohn's disease, or ulcerative colitis.
- •History of cardiac disease with a New York Heart Association Class II or greater, congestive heart failure, myocardial infarction, or unstable angina at any time during the 6 months prior to randomization, or serious arrhythmias requiring medication for treatment.
- •Current CTCAE ≥ grade 3 diarrhea.
- •Current chronic infection or uncontrolled serious illness causing immunodeficiency.
- •Known or suspected hypersensitivity or intolerance to arfolitixorin, LV, 5-FU, oxaliplatin, or bevacizumab.
- •Breastfeeding patients.
- •Patient who received investigational drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug, prior to randomization.
- •Patient with serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Ongoing drug or alcohol abuse, as deemed by the Investigator.
- •Any condition that, in the opinion of the Investigator, could compromise the patient's safety or adherence to the study protocol.
- •Involvement, or related to people involved in the planning or conduct of the study (applies to both Isofol Medical AB (publ) staff and staff at the study site)
- •Surgery (excluding previous diagnostic biopsy) in the 28-day period before randomization
研究组 & 干预措施
Group A
Experimental
ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
干预措施: Arfolitixorin (Drug)
Group B
Active Comparator
mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
干预措施: Leucovorin (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Until disease progression, an average of ten months
Best ORR, defined as the best response recorded from the start of the study treatment until the end of treatment.
次要结局
- Progression Free Survival(Until disease progression, an average of ten months)
- Duration of Response(Until disease progression, an average of ten months)
研究者
研究点 (94)
Loading locations...
相似试验
已完成
3 期
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.AsthmaNCT01686633GlaxoSmithKline1,040
已完成
3 期
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsUlcerative ColitisNCT02136069Hoffmann-La Roche397
已完成
3 期
A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute BronchitisAcute BronchitisNCT05344638Ahn-Gook Pharmaceuticals Co.,Ltd220
进行中（未招募）
3 期
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.HER2-positive Breast CancerNCT05985187Chia Tai Tianqing Pharmaceutical Group Co., Ltd.412
已完成
3 期
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic ChemotherapyChemotherapy-induced Nausea and VomitingNCT01500226Tesaro, Inc.1,369